Preprint Review Version 2 Preserved in Portico This version is not peer-reviewed

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Version 1 : Received: 20 January 2024 / Approved: 21 January 2024 / Online: 22 January 2024 (04:34:22 CET)
Version 2 : Received: 23 January 2024 / Approved: 24 January 2024 / Online: 24 January 2024 (05:48:05 CET)

A peer-reviewed article of this Preprint also exists.

Nayan, M.U.; Panja, S.; Sultana, A.; Zaman, L.A.; Vora, L.K.; Sillman, B.; Gendelman, H.E.; Edagwa, B. Polymer Delivery Systems for Long-Acting Antiretroviral Drugs. Pharmaceutics 2024, 16, 183. Nayan, M.U.; Panja, S.; Sultana, A.; Zaman, L.A.; Vora, L.K.; Sillman, B.; Gendelman, H.E.; Edagwa, B. Polymer Delivery Systems for Long-Acting Antiretroviral Drugs. Pharmaceutics 2024, 16, 183.

Abstract

Long-acting (LA) drug-delivery system (DDS) successes are linked to their abilities to harness biocompatible polymers and materials for sustained and predictable release of therapeutic agents over an extended period of time. For human immune deficiency virus type one (HIV-1) infections, LA DDSs hold great promise in closing the gaps of daily oral therapy for treatment and prevention. Examples are Cabenuva, Apretude and Sunlenca, which have been shown to be safe and effective. Alternative promising drug delivery technologies such as implants, prodrugs, vaginal rings, and microarray patches are being explored to further meet patients’ needs. We posit that improved physicochemical properties of the formulation payloads and material chemistry design with optimal drug release kinetics holds the potential to optimize release profiles. Furthermore, for the treatment and prevention of HIV-1 infection, the landscape of LA medicines now in clinical or preclinical development offers hope that the strategic design of polymers will further improve upon controlled delivery of drugs to simplify dosing schedules.

Keywords

long-acting formulations; polymer; antiretroviral therapy; HIV; chronic infectious diseases; implants; vaginal rings; prodrug nanoformulations; microarray patches

Subject

Medicine and Pharmacology, Medicine and Pharmacology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.